Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 - Tiziana Life Sciences, Ltd. , a biotechnology company developing breakthrough...
Takeda TSE4502NYSETAK today announced the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase in patients with chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy after stabilization with intravenous immunoglobulin therapy IVIG.
If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcutaneous…
15.12.2023 - Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] ...
René van der Merwe, MBChB, appointed as Chief Medical Officer Tapan Maniar, Ph.D., joins as Chief Business Officer Company on track to initiate a Phase 2…